Skip to main content

and
  1. Article

    Open Access

    Aberrant upregulation of the glycolytic enzyme PFKFB3 in CLN7 neuronal ceroid lipofuscinosis

    CLN7 neuronal ceroid lipofuscinosis is an inherited lysosomal storage neurodegenerative disease highly prevalent in children. CLN7/MFSD8 gene encodes a lysosomal membrane glycoprotein, but the biochemical process...

    Irene Lopez-Fabuel, Marina Garcia-Macia, Costantina Buondelmonte in Nature Communications (2022)

  2. Article

    Open Access

    Author Correction: Global network analysis in Schizosaccharomyces pombe reveals three distinct consequences of the common 1-kb deletion causing juvenile CLN3 disease

    Christopher J. Minnis, StJohn Townsend, Julia Petschnigg in Scientific Reports (2021)

  3. Article

    Open Access

    Guidelines on the diagnosis, clinical assessments, treatment and management for CLN2 disease patients

    CLN2 disease (Neuronal Ceroid Lipofuscinosis Type 2) is an ultra-rare, neurodegenerative lysosomal storage disease, caused by an enzyme deficiency of tripeptidyl peptidase 1 (TPP1). Lack of disease awareness a...

    Sara E. Mole, Angela Schulz, Eben Badoe in Orphanet Journal of Rare Diseases (2021)

  4. Article

    Open Access

    Global network analysis in Schizosaccharomyces pombe reveals three distinct consequences of the common 1-kb deletion causing juvenile CLN3 disease

    Juvenile CLN3 disease is a recessively inherited paediatric neurodegenerative disorder, with most patients homozygous for a 1-kb intragenic deletion in CLN3. The btn1 gene is the Schizosaccharomyces pombe ortholo...

    Christopher J. Minnis, StJohn Townsend, Julia Petschnigg in Scientific Reports (2021)

  5. No Access

    Chapter and Conference Paper

    Gene Therapy Approaches to Treat the Neurodegeneration and Visual Failure in Neuronal Ceroid Lipofuscinoses

    Neuronal ceroid lipofuscinoses (NCLs) are a group of fatal, inherited lysosomal storage disorders mostly affecting the central nervous system of children. Symptoms include vision loss, seizures, motor deterior...

    Sophia-Martha kleine Holthaus, Alexander J. Smith in Retinal Degenerative Diseases (2018)

  6. Article

    Open Access

    Analysis of Potential Biomarkers and Modifier Genes Affecting the Clinical Course of CLN3 Disease

    Mutations in the CLN3 gene lead to juvenile neuronal ceroid lipofuscinosis, a pediatric neurodegenerative disorder characterized by visual loss, epilepsy and psychomotor deterioration. Although most CLN3 patients...

    Anne-Hélène Lebrun, Parisa Moll-Khosrawi, Sandra Pohl in Molecular Medicine (2011)

  7. No Access

    Article

    Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses

    The neuronal ceroid lipofuscinoses (NCLs) are a group of severe neurodegenerative diseases with onset usually in childhood and characterised by the intracellular accumulation of autofluorescent storage materia...

    Sara E. Mole, Ruth E. Williams, Hans H. Goebel in Neurogenetics (2005)

  8. No Access

    Article

    Epitope map**

    This article describes a strategy for the map** of the binding site, or epitope, of a monoclonal antibody (MAb) using bacterially expressed protein products. An overall strategy is discussed. This includes a...

    Sara E. Mole in Molecular Biotechnology (1994)

  9. No Access

    Article

    Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A

    MULTIPLE endocrine neoplasia type 2A (MEN 2A) is a dominantly inherited cancer syndrome that affects tissues derived from neural ectoderm. It is characterized by medullary thyroid carcinoma (MTC) and phaeochro...

    Lois M. Mulligan, John B. J. Kwok, Catherine S. Healey, Mark J. Elsdon in Nature (1993)

  10. No Access

    Protocol

    Epitope Map**

    Monoclonal antibodies (MAbs) are specific immunological tools because they bind to a precise determinant (the epitope) on the surface of a protein. The procedure of identifying the binding site of a MAb is oft...

    Sara E. Mole in Immunochemical Protocols (1992)